Trinity Partners announced today the findings of its first annual ‘Trinity Drug Index,’ a comprehensive research-based report which assessed 22 novel drugs approved by the FDA in 2013. The Index rates drug performance as measured by a retrospective look at commercial success relative to therapeutic value and R&D complexity, assigning each drug a score in those three areas as well as an overall composite score.
Top findings of this year’s Trinity Drug Index include:
- Sovaldi, which treats Hepatitis C, received the highest ranking with an overall score of 4.4 out of 5
- Most of the top performers were specialty drugs
- Drugs for primary care markets such as COPD and diabetes tend to show weaker differentiation and limited commercial performance, exacerbated by significant R&D expense
- Commercial underperformance given significant therapeutic value is rare, and could be due to a rapidly changing competitive environment
- Well-executed business strategy may boost commercial performance of drugs that are not vastly superior therapeutically
- Moving forward, it will be more critical than ever to demonstrate a product’s value vis-à-vis existing competition
If you would like to read the full whitepaper, it is available for free on the Trinity Partners website HERE.